Improving CAR T cell therapy for Hodgkin Lymphoma
Tailoring CAR T cell therapy for Hodgkin Lymphoma
This study is testing a new treatment for people with Hodgkin Lymphoma that uses specially modified immune cells to better find and attack cancer cells, and it's designed for those whose cancer has come back or hasn't responded to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10866397 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR T cell therapy specifically for patients with Hodgkin Lymphoma and other CD30+ malignancies. The approach involves engineering T cells to express a chimeric antigen receptor (CAR) that targets the CD30 antigen, combined with a chemokine receptor to improve the T cells' ability to migrate to tumors. A phase I clinical trial will be conducted to assess the safety and effectiveness of this therapy in patients with relapsed or refractory Hodgkin Lymphoma. Patients will be monitored for immune responses and tumor interactions to better understand the therapy's impact.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed or refractory Hodgkin Lymphoma or other CD30+ malignancies.
Not a fit: Patients with CD30-negative malignancies or those who are not relapsed or refractory may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Hodgkin Lymphoma, potentially increasing the chances of complete remission.
How similar studies have performed: Previous studies have shown promise with CAR T cell therapies in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Savoldo, Barbara — Univ of North Carolina Chapel Hill
- Study coordinator: Savoldo, Barbara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.